AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01506739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: Drug E2020 dry syrup 1% form (suspended): E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose after suspended in 20 ml water.
Study NCT01506739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: Drug E2020 dry syrup 1% form: E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose with 200 mL water.
Study NCT02357836 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Itraconazole
Description: Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, Post-treatment assessments will include a skin biopsy, blood draw for the PK (pharmacokinetics) analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure.
Study NCT00752375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim Sulfamethoxazole
Description: * Children >3months of age will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)per day for one year.~* Children under 3 months of age will receive amoxicillin 10mg/kg once per day for one year.~* Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day for one year.
Study NCT00752375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: * Placebo matching Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)for children more than 3 months of age~* Placebo matching amoxicillin 10mg/kg once per day for children under 3 months of age~* Placebo matching nitrofurantoin (1mg/kg) once per day for children with a sulfa allergy.
Study NCT03397212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NADA acupuncture
Description: Ear acupuncture protocol described by National Acupuncture Detoxification Association
Study NCT03397212 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Ear acupuncture using inactive sham points
Study NCT00360971 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: neck dissection
Description: A neck dissection is required for patients with persistent nodal disease, any stage, if a palpable abnormality or worrisome radiographic abnormality persists in the neck 8-9 weeks after completion of therapy. A neck dissection is optional for patients with multiple positive lymph nodes or with lymph nodes exceeding 3 cm in diameter at pre-treatment (N2a, N2b, N3) who achieve a complete clinical and radiographic response in the neck. All patients will be assessed at approximately 8 weeks post-treatment with CT scan or MRI by the same technique used at baseline.
Study NCT04050592 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Estradiol
Description: Active intervention is estradiol. Hormone therapy (HT) of all 150 participants will be standardized to 2.0 mg of oral estradiol (E2) without progestogen for six weeks prior to randomization. After that participants will be randomized into three groups (A, B, C) of equal size.
Study NCT04050592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: Active intervention is estradiol. Hormone therapy (HT) of all 150 participants will be standardized to 2.0 mg of oral estradiol (E2) without progestogen for six weeks prior to randomization. After that participants will be randomized into three groups (A, B, C) of equal size.
Study NCT04050592 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Those in groups A and B will switch from estradiol to placebo at the beginning of the 10th week after abrupt or tapered discontinuation of HT.
Study NCT01205685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: In a pill form by mouth, twice a day (12 hours apart)~During the safety run portion of the study~* Dose level 2 = 150 mg twice a day~* Dose level 1 = 100 mg twice a day~* Dose level -1 = 100 mg twice a day~* Dose level -2 = 100 mg twice a day
Study NCT01205685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: During the safety run phase of the study:~* Dose Level 2 = 100 mg/d~* Dose Level 1 = 100 mg/d~* Dose Level -1= 75 mg/d~* Dose Level -2 = 50 mg/d
Study NCT00360971 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: A radiation dose of 70 Gy with at least 66 Gy to at least 2 mucosal sites of the oral cavity/oropharynx mucosa. Radiation therapy can be given with 3D conformal (3D-CRT) or with intensity modulated RT (IMRT) techniques; however, the chosen modality must be used for the entire course of treatment.
Study NCT00360971 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiation therapy
Description: A radiation dose of 70 Gy with at least 66 Gy to at least 2 mucosal sites of the oral cavity/oropharynx mucosa. Radiation therapy can be given with 3D conformal (3D-CRT) or with intensity modulated RT (IMRT) techniques; however, the chosen modality must be used for the entire course of treatment.
Study NCT03623100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Production Treatment.
Description: Speech production treatment will be delivered in two phases: Imitation and Spontaneous Production. Treatment will be provided two times weekly in 1-hour sessions, for up to 19 sessions. Every child's intervention program will target a single phoneme that was excluded from his or her phonemic inventory. Each treatment phoneme will be targeted through the production of five words that will be initially introduced to the child using a storybook reading format. Imitation treatment will continue until a child maintains 75% accurate production of the treated phoneme over two consecutive sessions (i.e. performance-based criterion) or until seven consecutive sessions are completed (i.e. time-based criterion). Spontaneous Production will continue until the child maintains either a performance-based criterion of 90% accurate production of the treated phoneme over 3 consecutive sessions, or a time-based criterion of 12 consecutive sessions.
Study NCT03623100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Production + Speech Perception Treatment.
Description: This speech treatment condition will be administered in the same way as the Speech Production treatment. The difference in conditions will be that speech treatment in this condition will last for 50 minutes rather than 60 minutes. The remaining 10 minutes of each session will involve the speech perception training. These speech perception tasks will involve previously recorded word-level productions focusing on the same phoneme that is addressed in speech production treatment in word-initial position. A variety of words produced correctly and incorrectly by adults and children will be presented in pairs and the children will have to determine if the words contain the same word-initial phoneme or two different phonemes.
Study NCT02819271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXL-1427 Ascending Dose
Study NCT02819271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02819271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXL-1427 Descending Dose
Study NCT02200016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided short axis (SAX) placement of sciatic nerve catheters
Description: Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the short axis of the sciatic nerve behind the knee.
Study NCT02200016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided long axis (LAX) placement of sciatic nerve catheters
Description: Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the long axis of the sciatic nerve behind the knee.
Study NCT02200016 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B Braun Contiplex S catheter
Study NCT02200016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B Braun Contiplex S catheter
Study NCT03959735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Description: HIIT is a type of exercise involving alternating short bursts of high intensity exercise with recovery periods of rest or light exercise.
Study NCT05753358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total Worker Health for Wildland Firefighters
Description: The program is structured as 30-minute modules that can be done individually, with a partner, as a group or in a classroom setting. The six core modules are supplemented with eight elective modules. The program can be accessed on a smartphone, tablet or computer, and if needed can be downloaded as a pdf.
Study NCT01527500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFG316
Description: LFG316 5 mg/50 μL solution for IVT injection,
Study NCT01527500 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham injection (akin to intravitreal injection but without intravitreal needle; no investigational drug given)
Study NCT01527500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFG316 Lower dose
Description: LFG316 5 mg/50 μL solution for IVT Injection
Study NCT02169245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary control of protein and fiber intake at breakfast
Description: Participants will be provided breakfast meals for 4, 2 week long interventions. The intervention arms are 1) average protein and fiber, 2) average protein and high fiber, 3) high protein and average fiber, and 4) high protein and fiber.
Study NCT00449033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Multikinase inhibitor, Sorafenib 400 mg po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m\^2 IV, Cisplatin 75 mg/m\^2 IV
Study NCT00449033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 tablets po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m\^2 IV, Cisplatin 75 mg/m\^2 IV
Study NCT00449033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Chemotherapy component; Gemcitabine 1250 mg/m\^2 IV
Study NCT00449033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy component; Gemcitabine 1250 mg/m\^2 IV
Study NCT00449033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Chemotherapy component; Cisplatin 75 mg/m\^2 IV
Study NCT00179153 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nepro nutritional supplement
Description: oral nutritional supplement (Nepro); every other day, 3 days per week, for 6 months
Study NCT03744065 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar plexus block
Description: Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, in the posteromedial quadrant of psoas muscle
Study NCT03744065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suprainguinal fascia iliaca block
Description: Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, underneath the fascia iliaca at the suprainguinal level
Study NCT04992481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PMTC
Description: In patients from the study groups I, II, III, IV a professional mechanical tooth cleaning (PMTC) including air-polishing was proceeded on every visit using a glycine-based prophylaxis powder (Air-Flow Soft, EMS, Switzerland).
Study NCT04992481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluoride varnish
Description: In patients from groups I, II, III, IV a fluoride varnish of 5% NaF (Profluorid Varnish, Voco, Germany) was applied with a microbrush. Every patient was instructed to stop from drinking and eating for the next two hours (as recommended by the manufacturer).
Study NCT04992481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gaseous ozone therapy
Description: Patients from groups II and IV were additionally subjected to in-office ozone therapy using OzonyTron-OZ (Mymed, Germany). Ozone was applied on a silicone double-jaw tray of a proper size (allowing even ozone distribution in the oral cavity) following professional mechanical tooth cleaning. A Full Mouth Desinfection program lasting 5 minutes was used.
Study NCT04992481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: domestic octenidin mouth rinse
Description: Patients from groups III and IV received a domestic mouthrinse (Octenidol MD, Schülke, Germany) and were recommended to use 15 ml of the liquid for 30 seconds after evening toothbrushing.
Study NCT04738188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DEB-TACE
Description: Drug-eluting beads transcatheter arterial chemoembolization
Study NCT04738188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cTACE
Description: Transcatheter arterial chemoembolization
Study NCT04738188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting Beads
Description: Drug-eluting beads
Study NCT01205685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: In a pill form, by mouth, once per day at 2.5 mg/d.
Study NCT01205685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: For pre-menopausal patients only. Given as an injection once a month at 3.6 mg/month.
Study NCT04738188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Chemotherapy drug for intra-arterial infusion
Study NCT04738188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Chemotherapy drug for intra-arterial infusion
Study NCT01142466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (Rebif)
Description: The dosage of IFN-beta-1a , following initial dose titration, was 44 mcg injected subcutaneously (s.c.) tiw. An auto-injector device, Rebiject, was available as an optional aid for the administration of IFN-beta-1a . IFN-beta-1a was administered, if possible, at the same time (preferably in the late afternoon or evening) on the same three days at least 48 hours apart each week.
Study NCT03648736 — intervention group
Intervention type: OTHER
Intervention: blood withdrawal
Description: * peripheral-venous before TASH, day 1, 2, 3, one week and one month after TASH procedure~* central-venous during TASH
Study NCT01593774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Tablet melatonin 3 mg/day at 9 pm as intervention group
Study NCT01593774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (with the same shape and taste as melatonin) at 9 pm as control group
Study NCT02748213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Participants will receive oral Xeloda, 950 mg/m\^2 twice a day on Days 1 to 14 of each 21-day cycle.
Study NCT02748213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Participants will receive Taxotere, 75 milligrams per meter-squared (mg/m\^2) in the Herceptin + Taxotere + Xeloda arm or 100 mg/m\^2 in the Herceptin + Taxotere arm, via IV infusion on Day 1 of each 21-day cycle. The lower starting dose will be used in the triple-therapy arm.
Study NCT00449033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy component; Cisplatin 75 mg/m\^2 IV
Study NCT00906685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Intravitreal injection of 1.25 mg bevacizumab
Study NCT01349699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron sucrose
Description: 1.25 mg/kg iron sucrose is administered intravenously 1 hr before endotoxin administration
Study NCT01349699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferasirox
Description: 30 mg/kg deferasirox is administered orally 2 hrs before endotoxin administration.
Study NCT01349699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: endotoxin
Description: at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
Study NCT01349699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: endotoxin
Description: at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
Study NCT01349699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At t=-2 hrs starch is dissolved in water to serve as a placebo for exjade. It is prepared and administered orally by a research nurse that is unblinded to the protocol.~At t=-1 hrs 0.9% NaCl is administered intravenously serving as a placebo for iron sucrose. The infused volume is identical, and the syringes en tubes are blinded by aluminum foil. The administration is carried out by a research nurse that is unblinded to the protocol.
Study NCT02259296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lower eGFR for AVF construction
Description: Lower eGFR patients (eGFR\<10ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR\<15ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
Study NCT02259296 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Higher eGFR for AVF construction
Description: Higher eGFR patients (eGFR 10-15ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR 15-20ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
Study NCT01116830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally daily for 6 weeks
Study NCT01116830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: 10 mg daily orally for 6 weeks
Study NCT01116830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Antipsychotic Therapy
Description: Participants will continue to receive their current antipsychotic treatment (as they are receiving at the time of screening). Protocol does not specify any particular standard antipsychotic therapy.
Study NCT01116830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Antipsychotic Therapy
Description: Participants will continue to receive their current antipsychotic treatment (as they are receiving at the time of screening). Protocol does not specify any particular standard antipsychotic therapy.
Study NCT01023022 — intervention group
Intervention type: OTHER
Intervention: Medtronic CareLink® Network
Description: The Medtronic CareLink® Network consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website
Study NCT00687128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-intensity treadmill exercise
Description: Treadmill walking at 30% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
Study NCT00687128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-intensity treadmill exercise
Description: Treadmill walking at 60% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
Study NCT00687128 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-aerobic stretching exercise
Description: Floor stretching exercise, 3-5 times per week at 20-60 minutes duration per session, progressive.
Study NCT00003778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolastatin 10
Study NCT01320514 — intervention group
Intervention type: DRUG
Intervention: Fibrin Sealant (Artiss)
Study NCT02524951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSI-1436C
Description: Dose escalation, single intravenous infusion twice a week for 3 weeks on a 4-week cycle.
Study NCT00906685 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham bevacizumab injection
Description: Sham intravitreal injection
Study NCT03349710 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day
Study NCT03349710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Specified dose on specified day
Study NCT03349710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified day
Study NCT03349710 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Specified dose on specified day
Study NCT05703477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
Study NCT00123487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablets, Oral, 70 mg BID, indefinitely, survival study
Study NCT00406575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was the diluent used for preparation of the 100 µg/kg/day dose of active study medication.
Study NCT00406575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human relaxin (rhRlx)
Description: Recombinant human relaxin (rhRlx) diluted for continuous IV infusion.